12 results
This study aims to evaluate the safety, tolerability and sedative proporties of a single dose of intransally administered dexmedetomidine in person odler than 65 years, differentiating between person using beta-blocking medication and those not…
The purpose of this study is to observe the usability of Dexmedetomidine and to determine the overall satisfaction of the patient.
Primary objective:the effects of sedation with clonidine or dexmedetomidine on the duration of haloperidol-resistent delirium in intensive care patientsSecondary objectives:the effect of treatment with clonidine or dexmedetomidine on1. total of…
Main objective: 1. Is there a 24hr-postoperative difference in immunological response between conventional and immune protective anesthesia?Secondary objectives:Is there a difference between patients with conventional and immune protective…
To demonstrate non-inferiority of conscious sedation with intranasal dexmedetomidine for performing dental care in patients with intellectual disability and dentophobia.
To determine the MTD toxicity of standard dose cetuximab together with concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine.
The aim of this study is to determine the patients* and endoscopists experiences and patients* safety with different sedation protocols.
The purpose of this study is to observe the usability of dexmedetomidine compared to the standard therapy (propofol) and to determine the overall satisfaction of the patient.
Our objective is to map the pharmacokinetic / pharmacodynamic interaction between dexmedetomidine and remifentanil by observing changes in anesthetic depth, measured by hypnotic and analgesic endpoints such as modified observer*s assessment of…
Primary objective:-To assess the efficacy of durvalumab plus olaparib combination therapy compared with durvalumab monotherapy in terms of PFS (Investigator-assessed)Secondary objectives:- To further assess the efficacy of durvalumab plus olaparib…
Primary objectivesTo compare overall survival for MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A to atezolizumab in combination with the background therapy of etoposide/platinum followed by…
Primary:To determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-5890 when used as monotherapy and in combination with pembrolizumab in the dose escalation and confirmation phase and the dose…